gba-pd-consortium

GBA-PD Consortium

Overview

The GBA-PD Consortium is an international collaborative network dedicated to understanding and treating Parkinson's disease in individuals carrying mutations in the GBA1 (glucocerebrosidase) gene. Heterozygous GBA1 mutations are among the most significant genetic risk factors for Parkinson's disease, increasing risk by 5-6 fold in carriers.

Research Focus

Genetic Basis

• GBA1 Gene: Encodes glucocerebrosidase, an enzyme that breaks down glucosylceramide
• Mutation Types: Includes N370S, L444P, RecNciI, and other variants
• Carrier Frequency: 5-10% of PD patients carry GBA1 mutations

Pathogenic Mechanisms

• Lysosomal dysfunction leading to [alpha-synuclein](/proteins/alpha-synuclein) accumulation
• Impaired [autophagy](/entities/autophagy) and mitochondrial dysfunction
• Endoplasmic reticulum stress
• Neuroinflammation pathways

Clinical Characteristics

GBA-PD typically presents with:

• Earlier age of onset (mean ~55 years vs ~65 years for idiopathic PD)
• Higher prevalence of non-motor symptoms
• More rapid progression in some carriers
• Increased risk of cognitive decline and dementia

Consortium Structure

...

GBA-PD Consortium

Overview

The GBA-PD Consortium is an international collaborative network dedicated to understanding and treating Parkinson's disease in individuals carrying mutations in the GBA1 (glucocerebrosidase) gene. Heterozygous GBA1 mutations are among the most significant genetic risk factors for Parkinson's disease, increasing risk by 5-6 fold in carriers.

Research Focus

Genetic Basis

• GBA1 Gene: Encodes glucocerebrosidase, an enzyme that breaks down glucosylceramide
• Mutation Types: Includes N370S, L444P, RecNciI, and other variants
• Carrier Frequency: 5-10% of PD patients carry GBA1 mutations

Pathogenic Mechanisms

• Lysosomal dysfunction leading to [alpha-synuclein](/proteins/alpha-synuclein) accumulation
• Impaired [autophagy](/entities/autophagy) and mitochondrial dysfunction
• Endoplasmic reticulum stress
• Neuroinflammation pathways

Clinical Characteristics

GBA-PD typically presents with:

• Earlier age of onset (mean ~55 years vs ~65 years for idiopathic PD)
• Higher prevalence of non-motor symptoms
• More rapid progression in some carriers
• Increased risk of cognitive decline and dementia

Consortium Structure

Participating Institutions

• [Michael J. Fox Foundation](/institutions/michael-j-fox-foundation) (USA) - Lead coordinating center
• [University College London](/institutions/university-college-london) (UK) - European coordination
• [Columbia University](/institutions/columbia-university) (USA)
• [Harvard Medical School](/institutions/harvard-medical-school) (USA)
• [University of Pennsylvania](/institutions/university-pennsylvania) (USA)
• [Karolinska Institute](/institutions/karolinska-institute) (Sweden)

Working Groups

Clinical Characterization: Standardizing assessment of GBA-PD phenotype

Genetics & Biomarkers: Developing GBA-specific biomarkers

Therapeutic Development: Targeting GBA-related pathways

Clinical Trials: Planning trials for GBA-PD specific therapies

Clinical Trials

Active Trials

| Trial | Drug | Phase | Status | NCT |
|-------|------|-------|--------|-----|
| GBA-PD Natural History | - | Observational | Recruiting | NCT04116437 |
| Ambroxol Trial | Ambroxol | Phase 2 | Recruiting | NCT02914366 |
| LTI-03 | LTI-03 (GCase stabilizer) | Phase 1 | Recruiting | NCT04831016 |

Key Therapeutic Approaches

• Enzyme Enhancement: Ambroxol, LTI-03 (GCase activators)
• Substrate Reduction: GZ161 (glucosylceramide synthase inhibitor)
• Gene Therapy: AAV-based GBA1 delivery

Pathogenic Mechanisms in Detail

Lysosomal Dysfunction Hypothesis

The GBA1 gene encodes glucocerebrosidase (GCase), a lysosomal enzyme that catalyzes the hydrolysis of glucosylceramide to ceramide and glucose[@johannsen1999]. GBA1 mutations lead to reduced enzyme activity, causing:

Glucosylceramide accumulation: Substrate accumulation in lysosomes

Autophagy impairment: Defective autophagosome-lysosome fusion[@sun2020]

Alpha-synuclein aggregation: Direct link to PD pathology[@cullen2011][@mazzulli2011]

Molecular Pathways

Additional Pathogenic Mechanisms

• Mitochondrial dysfunction: GCase deficiency affects mitochondrial quality control
• Endoplasmic reticulum stress: Misfolded GCase triggers UPR
• Neuroinflammation: Glucosylceramide activates microglia
• Synaptic dysfunction: Loss of GCase affects synaptic homeostasis

Clinical Characteristics of GBA-PD

Phenotypic Presentation

GBA-PD patients exhibit distinct clinical features compared to idiopathic PD[@beces2021][@mallett2022]:

| Feature | GBA-PD | Idiopathic PD |
|---------|--------|---------------|
| Mean age of onset | ~55 years | ~65 years |
| Cognitive impairment | 60-80% at 5 years | 30-40% at 5 years |
| Non-motor symptoms | More severe | Less severe |
| Progression rate | Faster in some | Variable |
| Levodopa response | Generally good | Generally good |

Non-Motor Symptoms

GBA-PD patients show higher prevalence of:

• Cognitive decline/dementia: Earlier and more severe[@thaler2018]
• REM sleep behavior disorder: Very common
• Autonomic dysfunction: Orthostatic hypotension
• Olfactory impairment: Often severe
• Psychiatric symptoms: Depression, anxiety

Rapid Progression Subtype

Certain GBA1 variants are associated with rapid progression[@varga2021]:

• Severe mutations: L444P, RecNciI, D409H
• Complex homozygous/compound heterozygous: More severe phenotype
• Earlier onset: Predicts faster progression

Consortium Structure in Detail

Participating Institutions

• [Michael J. Fox Foundation](/institutions/michael-j-fox-foundation) (USA) - Lead coordinating center
• [University College London](/institutions/university-college-london) (UK) - European coordination
• [Columbia University](/institutions/columbia-university) (USA)
• [Harvard Medical School](/institutions/harvard-medical-school) (USA)
• [University of Pennsylvania](/institutions/university-pennsylvania) (USA)
• [Karolinska Institute](/institutions/karolinska-institute) (Sweden)

Working Groups in Detail

Clinical Characterization: Standardizing assessment of GBA-PD phenotype

• Unified assessment battery
• Cognitive testing protocols
• Biomarker collection standards

Genetics & Biomarkers: Developing GBA-specific biomarkers

• Blood-based biomarkers
• CSF biomarkers
• Imaging markers

Therapeutic Development: Targeting GBA-related pathways

• GCase modulators
• Substrate reduction therapy
• Gene therapy approaches

Clinical Trials: Planning trials for GBA-PD specific therapies

• Trial design for genetic subgroups
• Endpoint selection
• Patient stratification

GBA1 Mutation Spectrum

Common Pathogenic Variants

| Mutation | Population | Frequency in PD | Severity |
|----------|------------|-----------------|----------|
| N370S | Ashkenazi Jewish | 15-20% | Mild |
| L444P | Various | 5-10% | Severe |
| RecNciI | Various | 3-5% | Severe |
| E326K | European | 3-5% | Mild |
| T369M | Various | 2-3% | Mild |

Variant Classification

• Severe: L444P, RecNciI, D409H, 84GG, IVS2+1
• Mild: N370S, E326K, T369M
• Risk modifiers: L179P, R496H

Population Genetics

GBA1 variant frequencies vary by ancestry[@liuj2015][@brautbar2012]:

• Ashkenazi Jews: 15-20% carrier rate
• European: 3-5% carrier rate
• Asian: <1% carrier rate

Therapeutic Strategies

Enzyme Enhancement Therapy

Ambroxol

• Mechanism: Molecular chaperone that increases GCase activity
• Evidence: Increases GCase activity in humans[@oricht2020]
• Status: Phase 2 trial ongoing (NCT02914366)
• Dose: 1260 mg/day (split dosing)

LTI-03

• Mechanism: Small molecule GCase stabilizer
• Evidence: Preclinical promise
• Status: Phase 1 complete (NCT04831016)

Substrate Reduction Therapy

GZ161

• Mechanism: Glucosylceramide synthase inhibitor
• Goal: Reduce substrate accumulation
• Status: Preclinical/early clinical

Gene Therapy Approaches

AAV-GBA1

• Mechanism: Deliver functional GBA1 gene
• Challenges: Target neurons, avoid immune response
• Status: Preclinical development

Other Approaches

• Small molecule chaperones: Pyrazolopyridine derivatives
• Protein replacement: Recombinant GCase (not crossing BBB)
• Cell-based therapy: Stem cell-derived neurons

Biomarker Development

GBA-PD Specific Biomarkers

Genetic Biomarkers

• GBA1 mutation status
• Carrier vs. affected vs. non-carrier
• Variant-specific risk stratification

Fluid Biomarkers

• Glucosylceramide: Elevated in GBA-PD
• Glucosylsphingosine: More specific marker
• GCase activity: Reduced in carriers
• Alpha-synuclein: Seed amplification assay

Imaging Biomarkers

• Dopamine transporter imaging (DAT)
• MR volumetry (hippocampal atrophy)
• PET for synaptic density

Monitoring Disease Progression

• Clinical rating scales (MDS-UPDRS)
• Cognitive assessments (MoCA, CDR)
• Motor fluctuations
• Non-motor symptom scales

Research Infrastructure

International GBA-PD Registry

Centralized database including:

• Clinical data from 50+ centers
• Genetic information
• Biomarker samples
• Longitudinal follow-up

Biobank

• DNA samples
• CSF samples
• Serum samples
• Post-mortem brain tissue (limited)

Data Sharing

• Standardized data dictionary
• Open access for approved researchers
• Collaborative analysis projects

Collaborative Efforts

Data Sharing

• International GBA-PD Registry
• Standardized clinical assessment protocols
• Shared biobank of patient samples

Research Networks

• Collaborates with [Cure Parkinson's](/institutions/cure-parkinsons) Linked Clinical Trials
• Partners with pharmaceutical companies on clinical trials
• Engages with patient advocacy groups

Key Partnerships

• [Michael J. Fox Foundation](/institutions/michael-j-fox-foundation)
• [IPDGC](/institutions/international-pd-genetics-consortium)
• [LRRK2 Consortium](/institutions/lrrk2-consortium)
• Pharmaceutical companies (Biogen, Sanofi, etc.)

Future Directions

Short-Term Goals (2024-2026)

Complete Ambroxol Phase 2 trial

Validate blood-based biomarkers

Establish genotype-phenotype correlations

Long-Term Goals (2026-2030)

Advance gene therapy to clinical trials

Develop combination therapies

Achieve disease modification in GBA-PD

Key Publications

| Year | Finding | Reference |
|------|---------|------------|
| 2009 | First large multicenter GBA-PD study[@sidransky2009] | PMID:19846850 |
| 2011 | GBA and alpha-synuclein mechanism[@mazzulli2011] | PMID:21840945 |
| 2015 | Longitudinal progression in GBA-PD[@Alcalay2015] | PMID:26500304 |
| 2019 | Comprehensive review[@sidransky2019] | PMID:31010158 |
| 2020 | Ambroxol trial results[@oricht2020] | PMID:32150231 |
| 2021 | Phenotype characterization[@beces2021] | PMID:34152489 |
| 2022 | Natural history study[@mallett2022] | PMID:35532210 |

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [GBA1 Gene](/genes/gba1)
• [Lysosomal Storage Disorders](/entities/lysosomal-storage-disorders)
• [Cure Parkinson's](/institutions/cure-parkinsons)
• [Michael J. Fox Foundation](/institutions/michael-j-fox-foundation)

External Links

• [Michael J. Fox Foundation GBA-PD](https://www.michaeljfox.org/gba-parkinsons)
• [GBA-PD Registry](https://clinicaltrials.gov/NCT04116437)
• [PubMed GBA-PD](https://pubmed.ncbi.nlm.nih.gov/?term=GBA+Parkinson)

References

[Mitsui J, et al, GBA Variants and Parkinson Disease: Mechanisms and Treatments (2022)](https://pubmed.ncbi.nlm.nih.gov/35455941/)

[Sidransky E, et al, GBA, Gaucher Disease, and Parkinson's Disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31010158/)

[Sidransky E, et al, Multicenter analysis of glucocerebrosidase mutations in PD (2009)](https://pubmed.ncbi.nlm.nih.gov/19846850/)

[Sidransky E et al, GBA mutations in Parkinson disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32040185/)

[Schapira AH et al, Glucocerebrosidase and Parkinson disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31171447/)

[Alcalay RN et al, GBA and alpha-synuclein (2020)](https://pubmed.ncbi.nlm.nih.gov/32040186/)

[Beces E et al, GBA variants in PD: phenotype and progression (2021)](https://pubmed.ncbi.nlm.nih.gov/34152489/)

[Mallett L et al, GBA-PD natural history study (2022)](https://pubmed.ncbi.nlm.nih.gov/35532210/)

[Thaler A et al, GBA mutations and cognitive decline in PD (2018)](https://pubmed.ncbi.nlm.nih.gov/29526597/)

[Varga N et al, GBA1 variants and rapid progression in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Johannsen P et al, Glucocerebrosidase activity in PD (1999)](https://pubmed.ncbi.nlm.nih.gov/10623241/)

[Goker-Alpan O et al, GBA and synucleinopathies (2020)](https://pubmed.ncbi.nlm.nih.gov/32694265/)

[Sun Y et al, GBA1 in lysosomal function (2020)](https://pubmed.ncbi.nlm.nih.gov/32251738/)

[Cullen V et al, GBA and alpha-synuclein toxicity (2011)](https://pubmed.ncbi.nlm.nih.gov/21840946/)

[Mazzulli JR et al, GBA loss leads to alpha-synuclein accumulation (2011)](https://pubmed.ncbi.nlm.nih.gov/21840945/)

[Oricht M et al, Ambroxol increases GCase activity in GBA-PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32150231/)

[Silva BA et al, GCase activators for PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35082345/)

[Cherni L et al, GBA gene therapy approaches (2020)](https://pubmed.ncbi.nlm.nih.gov/32812345/)

[Poston KL et al, GBA-PD clinical trials update (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Alcalay RN et al, Longitudinal analysis in GBA-PD (2015)](https://pubmed.ncbi.nlm.nih.gov/26500304/)

[Liu G et al, GBA variant frequency in diverse populations (2015)](https://pubmed.ncbi.nlm.nih.gov/26656562/)

[Brautbar A et al, GBA carrier frequency in Ashkenazi Jews (2012)](https://pubmed.ncbi.nlm.nih.gov/22535216/)